Empower the patient in the daily management of his/her chronic disease, by providing information about the pathology and offering daily activities and recipes to reduce risks of cardiovascular events.
Servier puts the patient at the core of its activity. Creating innovative tools to help patients enhance their lives is our key challenge.
Provide personalized, certified, and updated content for patients with multiple cardiovascular risks to have a healthier life.
An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths.1 Because most CVDs can be prevented, people with cardiovascular disease or who are high cardiovascular risk (due to the presence of one or more risk factors such as hypertension, diabetes…) need reliable and certified content that is dynamic, with personalized advice according to their diseases and interests.
Myhealthpartner.com will select and suggest specific content for you, based on its relevance to your own conditions, via specific questions during the first visit to the platform (age, lifestyle, conditions, etc). No personal data is recorded, and some of the content of the platform will be automatically customized according to your answers.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests in average 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer, and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
We are committed to therapeutic progress to serve patient needs.